Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR in inadequately controlled acromegaly
CTR20160324Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of pasireotide LAR in acromegaly, sponsored by Novartis. Started Sep 2016; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on CTR20160324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160324.